ELI LILLY AND COMPANY Increase (Decrease) in Other Operating Assets
ELI LILLY AND COMPANY (LLY) reported Increase (Decrease) in Other Operating Assets of $3.45 billion for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2024-02-21
- ELI LILLY AND COMPANY increase (decrease) in other operating assets for fiscal 2023 was $3.45B, a 335.21% increase from fiscal 2022.
- ELI LILLY AND COMPANY increase (decrease) in other operating assets for fiscal 2022 was $793.50M.
- ELI LILLY AND COMPANY increase (decrease) in other operating assets for fiscal 2021 was -$1.52B, a 431.52% decline from fiscal 2020.
- ELI LILLY AND COMPANY increase (decrease) in other operating assets for fiscal 2020 was $457.10M, a 24.11% decline from fiscal 2019.
| Period end | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|
| 2023-12-31 | $3.45B 10-K · filed 2024-02-21 | |
| 2022-12-31 | $793.50M 10-K · filed 2024-02-21 | |
| 2021-12-31 | -$1.52B 10-K · filed 2024-02-21 | |
| 2020-12-31 | $457.10M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $602.30M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $980.00M 10-K · filed 2021-02-17 | |
| 2017-12-31 | $590.10M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $265.50M 8-K · filed 2019-10-24 | |
| 2015-12-31 | $288.50M 10-K · filed 2018-02-20 | $338.80M 10-K · filed 2016-02-19 |
| 2014-12-31 | -$673.20M 10-K · filed 2017-02-21 | -$411.50M 10-K · filed 2015-02-19 |
| 2013-12-31 | -$116.50M 10-K · filed 2016-02-19 | |
| 2012-12-31 | -$231.00M 10-K · filed 2015-02-19 | |
| 2011-12-31 | -$642.70M 10-K · filed 2014-02-19 | |
| 2010-12-31 | -$340.50M 10-K · filed 2013-02-21 | $340.50M 10-K · filed 2011-02-22 |
| 2009-12-31 | $84.90M 10-K · filed 2012-02-24 | -$84.90M 10-K · filed 2010-02-22 |
| 2008-12-31 | $1.65B 10-K · filed 2011-02-22 | |
| 2007-12-31 | -$355.80M 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |